Press Releases - 2022-01-05
PureTech Founded Entity Gelesis Appoints Inogen Co-Founder and Former CFO Ali Bauerlein to Board of Directors and Audit Committee
Press Releases - 2021-12-08
Wholly Owned Pipeline
Wholly Owned Pipeline - LYT-300
PureTech Presents Preclinical Proof-of-Concept Data for LYT-300 (Oral Allopregnanolone) as Potential Treatment for Neurological and Neuropsychological Conditions
Press Releases - 2021-12-07
Wholly Owned Pipeline
Wholly Owned Pipeline - LYT-300
PureTech Advances Wholly-Owned Candidate LYT-300 (Oral Allopregnanolone) into Clinical Study for Potential Treatment of Neurological and Neuropsychological Conditions
Press Releases - 2021-12-01
PureTech Founded Entity Gelesis Announces FDA-Cleared Weight Management Approach, Plenity®, Now Broadly Available and Leading Nutrition Authority Joy Bauer, MS, RDN, CDN, Joins as Chief Nutrition Officer
Press Releases - 2021-11-16
Wholly Owned Pipeline
Wholly Owned Pipeline - LYT-100
PureTech Announces Publication of Phase 1 Results for LYT-100 in the Journal Clinical Pharmacology in Drug Development and Provides Timing Updates
Press Releases - 2021-11-12
Wholly Owned Pipeline
Wholly Owned Pipeline - LYT-200
PureTech Presents Clinical Trial Design Supporting Wholly Owned Immuno-Oncology Candidate LYT-200 at the Society for Immunotherapy of Cancer (SITC) 36th Annual Meeting
Press Releases - 2021-11-11
Wholly Owned Pipeline
Wholly Owned Pipeline - LYT-200
PureTech Receives Orphan Drug Designation for Wholly Owned Candidate LYT-200 for the Treatment of Pancreatic Cancer
